Cite
HARVARD Citation
Landewé, R. et al. (2010). Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the rheumatic diseases. 69 (9), pp. 1655-1659. [Online].